ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1715925
| Field | Detail |
|---|---|
| Company | Immunoprecise Antibodies LTD. (HYFT) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, press-release
TL;DR
IPA files 6-K, includes Sept 26 press release. Standard reporting update.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 26, 2024, reporting a press release dated September 26, 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The company's principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on ImmunoPrecise Antibodies Ltd.'s reporting status and includes a press release, which may contain important business or financial information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release and confirm reporting status, with no immediate indication of significant new risks.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Signatory for the company
- September 26, 2024 (date) — Filing date and press release date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, primarily to report a press release dated September 26, 2024.
What is the filing date of this report?
The filing date of this report is September 26, 2024.
Which annual report form does ImmunoPrecise Antibodies Ltd. file?
ImmunoPrecise Antibodies Ltd. files its annual reports under cover of Form 20-F.
Where is ImmunoPrecise Antibodies Ltd.'s principal executive office located?
The principal executive office of ImmunoPrecise Antibodies Ltd. is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated September 26, 2024, is included with this 6-K filing.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-09-26 09:13:32
Filing Documents
- press_release_sept_25_20.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 25KB
- 0000950170-24-109473.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 26, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer